Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etavopivat cardiac safety study in healthy volunteers
NCT07023029Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Jun 2025
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of etavopivat in sickle cell disease (SCD) (5 arms), sponsored by Novo Nordisk. Primary endpoints: Treatment-Emergent Adverse Events at 8 days and Change from Baseline in Fridericia Heart Rate Corrected QT Interval at 23 days. Started Jun 2025; status: completed.
02
Drugs
etavopivat
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT07023029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07023029.